Bio-Path Holdings

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BPTH and other ETFs, options, and stocks.

About BPTH

Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1001-A, BP1002, and BP1003.

CEO

Peter H. Nielsen

CEOPeter H. Nielsen

Employees

Employees10

Headquarters

Bellaire, Texas

HeadquartersBellaire, Texas

Founded

2007

Founded2007

Employees

Employees10

BPTH Key Statistics

Market cap

4.20M

Market cap4.20M

Price-Earnings ratio

-0.08

Price-Earnings ratio-0.08

Dividend yield

—

Dividend yield—

Average volume

8.78M

Average volume8.78M

High today

$2.79

High today$2.79

Low today

$2.60

Low today$2.60

Open price

$2.65

Open price$2.65

Volume

40.82K

Volume40.82K

52 Week high

$44.80

52 Week high$44.80

52 Week low

$2.60

52 Week low$2.60

BPTH News

Yahoo Finance 5d

Bio-Path Rises on Upbeat Updates From Blood Cancer Study - Yahoo Finance

Bio-Path Holdings, Inc. BPTH announced that it has completed the second dose cohort in the dose-escalation portion of an early-stage study evaluating its invest...

Benzinga 6d

Why Bio-Path Stock Is Soaring

Loading... Loading... Bio-Path Holdings, Inc. BPTH shares are trading higher Thursday after the company announced the completion of its second dose cohort in P...

TipRanks 6d

Bio-Path announces completion of higher dose second cohort in trial of BP1002

Bio-Path Holdings announced completion of the second dose cohort of the dose escalation portion of its Phase 1/1b clinical trial of BP1002 evaluating the abilit...